Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoxetic Acid-Enhanced MRI

Figure 3

Pre- and posttherapy liver images unenhanced (A, C) and 20 minutes after gadoxetic acid administration in the hepatobiliary phase (B, D) in a 68-year-old male patient with a decrease in relative liver enhancement (RLE) from 56% to 34%. Note the portosystemic collaterals (graded as major portosystemic collaterals) indicating clinically significant portal hypertension. (E–F) Pre- and posttherapy images in a 50-year-old male patient without portosystemic collaterals who had an increase in RLE from 31% to 112%.